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Abstract
The lung comprises an extensive surface of epithelia constantly exposed to environmental insults. Maintaining the integrity
of the alveolar epithelia is critical for lung function and gaseous exchange. However, following severe pulmonary damage,
what progenitor cells give rise to alveolar type I and II cells during the regeneration of alveolar epithelia has not been fully
determined. In this study, we have investigated this issue by using transgenic mice in which Scgb1a1-expressing cells and
their progeny can be genetically labeled with EGFP. We show that following severe alveolar damage induced either by
bleomycin or by infection with influenza virus, the majority of the newly generated alveolar type II cells in the damaged
parenchyma were labeled with EGFP. A large proportion of EGFP-expressing type I cells were also observed among the type
II cells. These findings strongly suggest that Scgb1a1-expressing cells, most likely Clara cells, are a major cell type that gives
rise to alveolar type I and II cells during the regeneration of alveolar epithelia in response to severe pulmonary damage in
mice.
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Introduction
It is predicted that lung diseases will rank second in terms of
prevalence, mortality, and healthcare costs [1,2]. The develop-
ment of lung regenerative medicine is limited by the relative lack
of knowledge about stem and progenitor cells and their identity,
organization and regulation in the adult lung [2]. The lung
comprises many types of epithelial cells that reside in anatomically
distinct regions of the trachea, bronchioles and alveoli [3–5]. In
the mouse, Clara cells are the predominant cell type in the
conducting airway, whereas alveolar epithelia are covered by
alveolar type I cells (AT1s) interspersed with alveolar type II cells
(AT2s). Clara cells are known as important progenitor cells for the
maintenance and repair of bronchiolar epithelia [6–8]. However,
the mechanism of alveolar epithelial regeneration, especially under
severe pathologic conditions, is still not clear. Most current
knowledge about the regeneration of damaged alveolar epithelia is
derived from studies of bleomycin-induced lung injury. Bleomycin
is a clinically important anti-cancer agent, but its use is restricted
by pulmonary toxicity, including induction of lung fibrosis [9–11].
Based on studies of bleomycin-induced alveolar damage, regen-
eration of alveolar epithelia has long been thought to be mediated
by proliferation of existing AT2s and their subsequent differen-
tiation into AT1s [12–14]. However, this notion was challenged by
a recent lineage tracing study showing that the newly generated
AT2s are not derived from the pre-existing AT2s [15]. Based on
morphological observations, a previous study also suggested that
bronchiolar cells may give rise to AT2s and AT1s during the
regeneration of alveolar epithelia [13]. However, this idea has not
attracted significant attention due to a lack of definitive evidence.
Recently, various lung stem and progenitor cells have been
identified. Bronchioalveolar stem cells (BASCs) express markers of
both Clara cells and AT2s, and reside at the broncho-alveolar duct
junction (BADJ) [16]. Sca-1 and CD34 are used to isolate these
putative BASCs [16], yet the validity of these markers has been
questioned by other groups [17,18]. In vitro, BASCs can be induced
to differentiate into both Clara cells and AT2s, while their function
as stem cells has yet to be evaluated by lineage tracing in vivo. A c-
kit-positive human lung stem cell was shown to give rise to
bronchioles, alveoli and pulmonary vessels after injection into the
damaged mouse lung [19]. A mouse lung stem cell was reported to
express integrin a6b4, and form clusters of Clara cells and AT2s in
kidney capsules when mixed together with fetal lung cells [15].
More recently, it was reported that p63-positive cells in the murine
distal lung may contribute to alveolar repair after influenza virus-
induced pulmonary injury [20]. However, none of these reported
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lung stem and progenitor cells has been unequivocally shown to
give rise to AT1s and AT2s during the regeneration of alveolar
epithelia by genetic lineage tracing in vivo [16,19–21].
In our study of Clara cells in lung damage repair, we employed
transgenic mice in which Scgb1a1-expressing cells and their
progeny can be genetically labeled with EGFP. Here, we show that
following bleomycin treatment or influenza virus infection, the
majority of the newly generated AT2s in the damaged parenchy-
ma were labeled with EGFP. A large proportion of EGFP-
expressing AT1s were also observed among the AT2s. These
findings strongly suggest that Scgb1a1-expressing cells, most likely
Clara cells, are a major cell type that gives rise to AT1s and AT2s
during the regeneration of alveolar epithelia in response to severe
pulmonary damage.
Results
In the normal mouse lung, the bronchiolar epithelia are covered
by Clara and ciliated cells, whereas the alveolar epithelia are
covered by AT1s interspersed with AT2s. We consistently
observed that staining of the Clara cell marker secretoglobin
family 1A member 1 [Scgb1a1 or Clara cell secretory protein
(CCSP)] was confined to bronchiolar epithelia and that staining of
the AT2 cell marker pro-surfactant protein C (pro-SPC) was
dispersed among AT1s that were positive for podoplanin (PDPN)
(Figure 1A, B). Lymphatic endothelial cells also express PDPN;
because there is no lymphatics in alveolar area [22] PDPN can
serve as a specific marker for AT1s. Bleomycin-induced alveolar
epithelial damage was observed as early as 3 days post treatment.
By 7 days post-treatment, large areas of alveolar epithelia lost both
PDPN and pro-SPC staining, while infiltrating cells were evident
as indicated by dense DAPI staining of nuclei (Figure 1C).
Influenza virus infection caused damages of both bronchiolar and
alveolar epithelia as early as 3 days post infection (dpi). Severe
infiltration in alveolar area and loss of AT2s and AT1s were
evident starting 5 dpi (Figure 1D).
Mice treated with bleomycin were visibly sick by 7 days post-
treatment; with some of them showing severe clinical signs after 14
days and had to be euthanized. By 21 days post-treatment, the
remaining mice appeared to have recovered from bleomycin
treatment, and immunofluorescent analysis of lung sections at day
21 revealed a reduced cell infiltration in the lungs. Strikingly, large
numbers of pro-SPC-positive AT2s were detected in clusters in the
damaged parenchyma (Figure 1E, F), consistent with previous
studies [12,13,15]. Similarly, in influenza virus-infected mice,
newly generated AT2s appeared in the damaged parenchyma
starting around 11 dpi, and large numbers of these cells were
observed by 17 dpi (Figure 1H). Importantly, PDPN-positive cells
with AT1 morphology were also detected among the newly
generated AT2s (Figure 1G, I), indicating the repair of the
damaged alveolar epithelia. These results suggest that both
bleomycin treatment and influenza virus infection induce alveolar
epithelial damages which are repaired during recovery.
To investigate the origin of the newly generated AT2s in the
damaged parenchyma, we assayed proliferation of AT2s and
Clara cells by BrdU labeling. Mice were infected with influenza
virus and every two days between day 3 and 21 post infection, a
group of mice were given BrdU for 2 hrs before analysis. Only a
small fraction of AT2s incorporated BrdU during the entire course
of the repair process. Quantification of representative BrdU stains
at 19 dpi showed only 2.661.1% (mean6SE, 3 mice) of AT2s in
the damaged parenchyma were labeled with BrdU and the labeled
cells were scattered among non-labeled AT2s (Figure 1J). In
contrast, a significant level of Clara cells was labeled with BrdU
starting 5 dpi and at the peak of BrdU incorporation (9 dpi)
32.761.1% (mean6SE, 3 mice) of Clara cells in the damaged
bronchioles were BrdU positive (Figure 1K). These results suggest
that most of the new AT2s may not be generated through
proliferation of pre-existing AT2s, consistent with the recent report
[15].
To investigate the role of Clara cells in the regeneration of
alveolar epithelia, we crossed Scgb1a1-CreER gene targeted mice
[7] with ACTB-mT-EGFP transgenic mice to generate Scgb1a1-
CreER:ACTB-mT-EGFP double transgenic mice. In this system,
a floxed tomato red (mT) cassette driven by the beta-actin
promoter (ACTB) is expressed in all cell types and tissues [23].
CreER recombinase under the control of the endogenous mouse
Scgb1a1 promoter is expressed in Scgb1a1-expressing cells but
retained in the cytoplasm. Following tamoxifen (TMX) treatment
of the mice, CreER is translocated into the nucleus where it
mediates recombination to activate the expression of EGFP by
deleting the mT cassette. Thus, Scgb1a1-expressing cells and their
progeny are labeled with EGFP following TMX treatment. EGFP
and mT signals can be directly detected from tissue sections after
formalin fixation and paraffin embedding.
To perform lineage tracing, we compared induction of EGFP-
positive cells in double-transgenic mice in the presence or absence
of TMX. In untreated double transgenic mice (without TMX), no
EGFP-positive cells were observed in the alveolar region, and only
,10% of Clara cells in the bronchioles were EGFP-positive
(Figure 2A, C). Following TMX treatment, approximately 85% of
Clara cells in the bronchioles were EGFP-positive (Figure 2B, C),
and ,7% of AT2s were also EGFP-positive. These results are
consistent with those reported previously [7]. Surprisingly, we
found that in the double transgenic mice even without TMX
treatment, a small fraction of AT2s in the damaged lung regions
were also labeled with EGFP during repair following either
bleomycin treatment or influenza virus infection (Figure 2D–G).
Since no alveolar cell was labeled by EGFP without injury and
without TMX treatment, the induction of EGFP-positive AT2s
following pulmonary damage in the absence of TMX treatment
raises the possibility that these cells are derived from pre-labeled
EGFP-positive Clara cells.
To further investigate this possibility, we analyzed induction of
EGFP-positive cells in double-transgenic mice following lung
injury in the presence of TMX. Transgenic mice were given TMX
first to induce EGFP expression in Scgb1a1-positive cells and then
treated with bleomycin or infected with influenza virus. Twenty-
one days post bleomycin treatment, large numbers of pro-SPC-
positive AT2s were observed to express EGFP throughout the
damaged regions (Figure 3A, B). Quantification of five consecutive
lung sections spanning more than 600 mm thickness showed that
77.961.6% (mean6SE) of AT2s were EGFP-positive. Among the
EGFP-positive AT2s, many AT1-like cells were also EGFP-
positive (Figure 3C, arrows). Confocal analysis of PDPN staining
of adjacent lung sections confirmed the presence of EGFP-positive
AT1 cells in the same region (Figure 3D–F, arrows). Similarly,
following influenza virus infection of TMX-treated transgenic
mice, EGFP-positive AT2s were also observed throughout the
newly regenerated alveolar regions (Figure 4A, B). Quantification
of EGFP-positive cells showed that 48.163.0% (mean6SE) of the
AT2s in the damaged parenchyma were positive for EGFP.
Furthermore, the EGFP-positive AT1s were also detected among
EGFP-positive AT2 cells (Figure 4C). In comparison, only very
few EGFP-positive AT2s were observed in the alveoli of non-
infected mice (Figure 4D, E). These results show that Scgb1a1-
expressing cells are the major cell types that give rise to the newly
generated AT1s and AT2s.
Scgb1a1-Expressing Cells Regenerate Alveoli
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Figure 1. Damage and repair of alveolar epithelia following bleomycin treatment or influenza virus infection. A. Representative lung
sections of untreated C57BL/6 (B6) mice displaying Scgb1a1 (green), pro-SPC (red) and DAPI (blue) staining. Higher magnification of the boxed area is
shown at the upper-right corner. B–D. Representative images of PDPN (green), pro-SPC (red) and DAPI (blue) staining of lung sections of untreated
B6 mice (B); or mice at 7 days post-treatment with bleomycin (C); or mice at 11 days post-infection with influenza virus (D). E&F. Representative
images of Scgb1a1(green), pro-SPC (red) and DAPI (blue) staining of lung sections of B6 mice at 21 days post-bleomycin treatment. Higher
magnification of the selected area is shown as (F). White broken line in (E) demarcates the damaged area (left) from the normal area (right) of the
lung. G–I. Representative images of PDPN (green), pro-SPC (red) and DAPI (blue) staining of lung sections of B6 mice at 21 days post-bleomycin
treatment (G), or at 21 days after virus infection (H). Higher magnification of the selected area in (H) is shown as (I). J–K. Representative images of pro-
SPC (red in J) or Scgb1a1 (red in K), BrdU (green) and DAPI (blue) staining of lung sections of B6 mice at 19 days (J) or 9 days (K) after virus infection,
arrows indicate pro-SPC and BrdU double positive (J) or Scgb1a1 and BrdU double positive (K) cells. Note, BrdU-positive cells that are outside of the
bronchiole in (K) are negative for pro-SPC. Scale bars: (A) 500 mm; (B, F, I–K) 50 mm; (C, D, G) 100 mm; (E) 1000 mm; (H) 200 mm. G and I not labeled.
doi:10.1371/journal.pone.0048451.g001
Figure 2. Induction of EGFP-positive AT2s in transgenic mice without TMX treatment. A&B. Representative images of bronchioles of
Scgb1a1-CreER:ACTB-mT-EGFP transgenic mice without (A) or with (B) TMX treatment. Expression of EGFP (green) and tomato red (mT, red) are
depicted. Sections were counterstained with DAPI (blue). C. Percentages (mean 6 S.E.) of Clara cells per bronchiole that expressed EGFP in Scgb1a1-
CreER:ACTB-mT-EGFP transgenic mice without or with TMX treatment. D–G. Scgb1a1-CreER:ACTB-mT-EGFP transgenic mice without TMX treatment
were treated with bleomycin (D) or infected with influenza virus (F). Shown are representative images of lung sections analyzed for expression of
EGFP (green) and tomato red (purple), and stained for pro-SPC (red) and Scgb1a1 (blue) at 21 days post-bleomycin treatment (D) or 17 days post-
infection (F). Higher magnification images of boxed areas in (D) and (F) are shown as (E) and (G), respectively. White broken line in (F) demarcates the
infiltrated area (left) from the normal area (right) of the lung. Scale bars: (A, B, D, F) 100 mm; (E, G) 50 mm.
doi:10.1371/journal.pone.0048451.g002
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Discussion
In this study, we investigated regeneration of alveolar epithelia
following severe lung damage induced by a small molecular weight
chemical (bleomycin) or a natural infectious agent (influenza virus).
Using lineage tracing, we provide definitive evidence showing that
Scgb1a1-expressing cells can differentiate into AT2s and AT1s to
repair the alveolar damage. After severe pulmonary damage
induced by either bleomycin treatment or influenza virus infection,
large proportions of newly generated AT2s and AT1s were labeled
with EGFP in Scgb1a1-CreER:ACTB-mT-EGFP double trans-
genic mice (Figure 3 and 4). While the present study was prepared
for publication, using tomato red as the genetic marker, Rock et al
reported the observation of tomato red-labeled AT2s and AT1s in
a similar lineage tracing system following bleomycin treatment
[14]. Compared to their study, which only used bleomycin and did
not quantify the percentage of labeled AT2s, we performed a more
quantitative analysis and also used a natural infectious agent
influenza virus besides bleomycin. Together, these findings
unequivocally demonstrate that labeled AT2s and AT1s are
derived from pre-labeled Scgb1a1-expressing cells.
In the Scgb1a1-CreER system, Cre-mediated recombination
labels predominantly Clara cells, some AT2s, BASCs and
occasionally ciliated cells [7] and therefore the EGFP-positive
AT1s and AT2s could originate from one of the four cell types.
Although the putative BASCs can differentiate into both Clara
cells and AT2s in vitro [16], they are too rare [16–18] to contribute
significantly to the newly generated EGFP-positive AT2s and
AT1s. Similarly, only ,0.4% of ciliated cells were labeled by
EGFP with or without TMX treatment [7]. They are unlikely to
have contributed significantly to the large numbers of the EGFP-
positive AT2s and AT1s following bleomycin treatment or
influenza infection. Approximately 7% of AT2s were labeled by
EGFP after TMX treatment without lung injury, raising the
possibility that these pre-labeled AT2s may give rise to the newly
generated EGFP-positive AT2s in the damaged parenchyma.
However, this is unlikely a major pathway for the following
reasons: First, after bleomycin treatment or influenza infection
there were almost no AT2s left in the damaged parenchyma
(Figure 1C, D). If TMX-induced EGFP-positive AT2s contributed
to the regeneration of AT2s in the damaged parenchyma, they
would have to come from un-damaged lung area. Currently, there
is no evidence supporting this mechanism. Second, for the 7% of
EGFP-positive AT2s to give rise to ,80% of EGFP-positive AT2s
following bleomycin treatment and 50% following influenza
infection, the 7% EGFP-positive cells would have to expand
disproportionally. However, only very few of AT2s were in
proliferation throughout the 21 days of the repair process that was
monitored in the present study (Figure 1J). Third, it is possible that
lung injury may induce expression of Scgb1a1 in the newly
generated AT2s. However, this alone should not induce more
EGFP-positive AT2s because Cre-mediated recombination also
requires TMX treatment. In our experimental system, TMX was
given at least one week before infection or bleomycin treatment,
whereas large numbers of new AT2s are not induced until two
weeks after lung injury. Finally, a recent study using direct lineage
tracing of AT2s in bleomycin-induced lung injury provides direct
evidence showing that the majority of the newly generated AT2s
are not derived from the pre-existing AT2s [15]. Therefore, the
7% pre-labeled AT2s in TMX treated mice are unlikely to give
rise to the majority of EGFP-expressing AT2s during the alveolar
regeneration following bleomycin treatment or influenza infection.
In contrast, 85% of Clara cells were labeled with EGFP
following TMX induction and they underwent rapid proliferation
following influenza induced damage of bronchiolar epithelia
(Figure 1K). There are sufficient numbers of EGFP-labeled Clara
cells that could give rise to a large number of AT2s and AT1s in
the damage parenchyma. In our lineage tracing system, not all the
Clara cells were labeled with EGFP, and hence not all the newly
generated AT2s were labeled. Furthermore, we show that when
most Clara cells (,85%) were labeled by EGFP after TMX
treatment (without lung injury), ,7% of AT2s were also positive
for EGFP. These EGFP-positive AT2s could be generated because
of weak expression of Scgb1a1 in a small portion of AT2s [7].
However, if Scgb1a1 transcript was restricted to the conducting
airways in mice [24], it is more likely that some EGFP-labeled
Clara cells naturally differentiate into AT2s in the absence of lung
injury. The fact that most of the EGFP-labeled AT2s were close to
BADJs strongly supports the latter possibility [7]. In addition, by
over-expression of fibroblast growth factor 10 (FGF10) or
activation of the Wnt/b-catenin signaling in combination with
expression of a mutant kras, two recent studies showed that Clara
cells can be induced to express pro-SPC and become stem cell/
progenitor-like cells [25,26], indicating the progenitor potential of
Clara cells for alveolar regeneration. Thus, although we could not
exclude completely the contribution of BASCs, ciliated cells,
existing AT2s or other progenitor cells to give rise to AT2s and
AT1s during the regeneration of new alveolar epithelia, our
findings support that a major fraction of the newly generated AT2s
are likely derived from Clara cells.
Our findings provide a possible explanation for other putative
stem and progenitor cells that were reported to give rise to AT2s.
For example, a recent study showed that a6b4-positive cells
isolated from adult mouse lung can give rise to Clara cells and
AT2s in kidney capsules when mixed together with fetal lung cells.
Since ,10% of the purified a6b4-positive cells were strongly
positive for Scgb1a1 [15], these pre-existing Clara cells may have
given rise to Clara cells and AT2s in the engrafted renal capsule.
More recently, p63+Krt14+Krt5+PDPN+ cells were observed in
the damaged lung parenchyma following influenza virus infection
and proposed to contribute to alveolar epithelial regeneration [20].
Even though these cells can be labeled in Krt14-CreER transgenic
system, stringent lineage tracing has yet to be performed. In our
study, following either bleomycin treatment or influenza virus
infection, PDPN-positive AT1s re-appeared in the damaged
parenchyma where there were large numbers of newly generated
AT2s. Such areas were no longer severely infiltrated, clearly
indicating the regeneration of damaged alveolar epithelia
(Figure 1), which is congruent with previous reports [12,13,15].
Our study reveals an underappreciated cellular mechanism
where Clara cells serve as the progenitors for alveolar epithelial
regeneration during severe lung damage repair and perhaps
during normal homeostasis. Although an early study suggested two
Figure 3. Observation of EGFP-positive AT2s and AT1s in TMX-treated transgenic mice after bleomycin treatment. A–C. Scgb1a1-
CreER:ACTB-mT-EGFP transgenic mice were given tamoxifen and then treated with bleomycin. Shown are representative images of lung sections
analyzed for EGFP (green), pro-SPC (red) and Scgb1a1 (blue) at 21 days post-treatment. Tomato red is not shown. Higher magnification of boxed area
in (B) is shown as (C). Arrows in (C) indicate EGFP-positive AT1-like cells. D–F. Representative images of confocal analysis for EGFP (D), PDPN (E) and
merged (F) of lung sectons from TMX-treated transgenic mice at 21 days post-bleomycin treatment. Arrows in (D–F) indicate EGFP and PDPN double-
positive AT1s. Scale bars: (A, B) 1000 mm; (C–F) 20 mm.
doi:10.1371/journal.pone.0048451.g003
Scgb1a1-Expressing Cells Regenerate Alveoli
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e48451
mechanisms, i.e. in damaged areas away from bronchioles,
alveolar epithelium is repaired via proliferation of existing AT2s;
whereas in areas near bronchioles, progenitor cells from bronchi-
olar epithelia may differentiate into AT2s to regenerate alveolar
epithelia [13]. For a long time, it is believed that the pre-existing
AT2s play the major role in alveolar epithelial regeneration. Using
a genetic lineage tracing system to specifically label AT2s, a recent
study showed that the newly generated AT2s are not from pre-
existing AT2s, indicating that other progenitor cells give rise to
new AT2s for the repair of alveolar epithelia [15]. By genetically
tracing Scgb1a1-expressing cells, our study provides most direct
evidence that Clara cells from bronchiolar epithelia likely play a
major role in alveolar epithelial regeneration following severe
pulmonary damage whether chemically or virally induced. Future
investigations on the cellular and molecular mechanisms of this
differentiation process will facilitate the search for novel
therapeutic strategies for severe pulmonary injury.
Materials and Methods
Mice, Influenza Virus Infection, and Chemical Treatment
C57BL/6 (B6) mice were purchased from the Center for
Animal Resources, Singapore. Transgenic ACTB-mT-EGFP
(stock number 007676) mice on the B6 background were
purchased from The Jackson Laboratories. Scgb1a1-CreER
knockin mice (MGI) on the B6 background were kindly provided
by Dr. Brigid Hogan of Duke University, USA. Double Scgb1a1-
CreER:ACTB-mT-EGFP transgenic mice were generated by
mating Scgb1a1-CreER mice with ACTB-mT-EGFP mice, and
progeny were screened according to the protocol provided by Dr.
Hogan’s laboratory. To induce Cre-mediated recombination,
Scgb1a1-CreER:ACTB-mT-EGFP transgenic mice were treated
with tamoxifen in corn oil (or corn oil only as control) every other
day for four times at a dose of 0.25 mg/g body weight [7]. One
week after the last TMX injection (or two weeks after the initiation
of TMX treatment) mice were infected with influenza virus A/
Puerto Rico/8/34 H1N1 (PR8). B6 and transgenic mice aged 8–
Figure 4. Observation of EGFP-positive AT2s and AT1s in TMX-treated transgenic mice after influenza virus infection. A–E.
Representative images of lung sections of TMX-treated Scgb1a1-CreER:ACTB-mT-EGFP transgenic mice after (at 21 dpi) (A–C) and before (D–E)
influenza infection. Expression of EGFP (green), tomato red (purple) and pro-SPC (red) are analyzed in (A, B, D, E). Higher magnification images of
selected areas in (A) and (D) are shown as (B) and (E), respectively. White broken line in (A) demarcates the infiltrated area (below) and normal area
(above). Expression of EGFP (green) and PDPN (red) with DAPI (blue) staining are analyzed in (C). Arrows in (E) indicate EGFP and PDPN double-
positive cells. Scale bars: (A, D) 500 mm; (B, E) 100 mm; (C) 20 mm.
doi:10.1371/journal.pone.0048451.g004
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12 weeks old were challenged with a sublethal dose of 100 pfu of
PR8 virus per mouse, or treated with bleomycin (0.5–1 U/kg body
weight) by intratracheal instillation under anesthesia. BrdU
solution (BD Pharmingen) was injected intraperitoneally 2 hours
before sacrifice at a dose of 50 mg/kg body weight. All animals
were housed and handled in biosafety level 2 animal facilities. All
animal protocols were approved by the Institutional Animal Care
and Use Committees of National University of Singapore and
Massachusetts Institute of Technology.
Antibodies for Immunochemistry
Polyclonal rabbit anti-Scgb1a1 antibody (US Biological, C5828)
was used at 1:200 dilution. Polyclonal goat anti-pro-SPC (Santa
Cruz Biotechnology, sc-7706), goat anti-PDPN (R&D Systems,
AF3244), rabbit anti-GFP (Abcam, ab290) and mouse anti-BrdU
(Leica Microsystems, NCL-BrdU) were used at a 1:50 dilution.
Secondary antibodies (including donkey anti-rabbit, anti-goat,
anti-rat, or anti-mouse), each with different Alexa Fluor conjuga-
tions, were all purchased from Life Technologies and used at
1:200 dilution.
Histopathology and immunohistochemical staining.
Mouse lung tissues were harvested and fixed in 10% neutral
buffered formalin solution (Sigma-Aldrich) for 24 h. The tissues
were processed with a tissue processor (Leica Microsystems)        and
embedded in paraffin. Sections were cut at 5 mm thickness,
mounted on polylysine-coated slides (Thermo Fisher Scientific),
dewaxed, and rehydrated. For immunofluorescent staining,
antigen retrieval was carried out by digestion in proteinase K
solution (Sigma-Aldrich, 20 ug/ml, in 50 mM Tris-Cl, 1 mM
EDTA, pH 8.0) at 37uC for 20 min. For BrdU staining, sections
were processed according to the manufacturer’s protocol. Sections
were then immersed for 1 h in blocking buffer (3% BSA, 0.2%
Triton X-100 in PBS), incubated with primary antibody (in
blocking buffer) at 4uC overnight, followed by incubation with
secondary antibody at 4uC for 1 h. Sections were mounted with
anti-fade reagent (Life Technologies), scanned with a high-
resolution MIRAX MIDI system (Carl Zeiss) equipped with both
bright field and fluorescence illumination. Images were analyzed
using the Mirax viewer software. Confocal microscopy was
performed using FluoView FV1000 (Olympus).
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